The Autoimmune Protocol and Inflammatory Bowel Disease: What the Research Shows

What You’ll Learn in This Article:

• Clinical remission outcomes from the first AIP intervention trial
• Changes in patient-reported quality of life
• Molecular insights from intestinal RNA expression analysis
• Long-term, real-world experiences and common food triggers

This collection of studies offers an early but compelling foundation for understanding how AIP may support individuals living with Crohn’s disease and ulcerative colitis.

From Anecdote to Evidence

Before AIP was ever studied formally, many people with IBD were already experimenting with the protocol in hopes of easing symptoms when conventional treatments fell short. Stories of reduced pain, fewer flares, improved digestion, and even remission circulated widely in online communities. These anecdotes were hopeful—but in medicine, experience alone is not considered evidence.

Over the past decade, that has begun to change. Researchers have started testing AIP in structured clinical settings, using validated tools to measure disease activity, inflammation, and quality of life. The first study launched in 2015, and since then AIP has been evaluated not only in IBD but in other autoimmune conditions, such as Hashimoto’s thyroiditis, rheumatoid arthritis, and psoriasis. While these studies are small and preliminary, they consistently point in the same direction: when implemented correctly, AIP may help reduce symptoms, modulate immune activity, and improve overall wellbeing.

For people with Crohn’s disease and ulcerative colitis—who often face limited treatment options or incomplete relief—this emerging evidence represents a meaningful and hopeful development.

Study 1: Pilot Study on Clinical Efficacy (Konijeti et al., 2017)

This landmark study, published in Inflammatory Bowel Diseases, was the first time AIP was evaluated in a clinical research setting. It examined whether AIP could induce remission in adults with active Crohn’s disease or ulcerative colitis—many of whom had long histories of refractory disease.

Study Design

This prospective cohort study included 15 adults with active inflammatory bowel disease (IBD). Participants had been living with their condition for an average of 19 years. Nearly half (47%) were already using biologic medications without achieving remission, while others were taking steroids, immunomodulators, or combination therapy—highlighting that this was a group with longstanding, active disease despite conventional treatment.

The intervention lasted 11 weeks and followed a structured, phased approach.

During the first six weeks, participants moved through a gradual transition phase. Two food groups were removed each week while nutrient-dense foods—such as organ meats, seafood, vegetables, and bone broth—were intentionally added. This stepwise method was designed to minimize overwhelm and help participants adapt both practically and physiologically.

The final five weeks consisted of full AIP elimination, with all protocol eliminations in place. In addition to dietary changes, participants focused on nutrient density, sleep, stress management, and gentle lifestyle modifications to support overall immune regulation.

The program was delivered using a group health coaching model based on Angie Alt’s “SAD to AIP in Six” framework, providing education, accountability, community support, and weekly guidance throughout the study.

Assessments

Researchers evaluated participants using a comprehensive set of measures to capture both objective and subjective outcomes. These included:

• Clinical disease activity scores
• Physician assessments
• Biomarkers
• Patient-reported outcomes
• In selected cases, endoscopy, radiology, or indicators of mucosal healing

This combination of tools allowed researchers to assess changes in symptoms, inflammatory activity, and overall disease status from multiple perspectives.

Study 1 Results

The outcomes of this pilot study were unusually strong for a short-term dietary intervention—especially given that participants had long-standing, treatment-resistant IBD. With an average disease duration of 19 years and many already using advanced medications without remission, this was not a mild or newly diagnosed population.

Clinical remission

By week six, 73% of participants achieved clinical remission. All participants who reached remission maintained it through week eleven, the end of the study.

These remission rates are notable for several reasons:

• The population included individuals with severe, longstanding disease.
• Nearly half were already on biologic therapy and had not achieved remission.
• Dietary interventions in IBD research rarely demonstrate remission rates this high or this rapid.

Even more striking was the timing of improvement. Most participants began experiencing significant symptom relief during the transition phase—before full AIP elimination was in place.

This suggests that early shifts alone may meaningfully influence disease activity, including:

• Reducing exposure to common inflammatory foods
• Increasing overall nutrient density
• Stabilizing gut function
• Supporting sleep and stress regulation

Together, these foundational changes may begin lowering inflammatory burden more quickly than previously assumed.

Medication changes

Four participants were able to reduce or discontinue medications—including steroids or biologics—under physician supervision.

Importantly:

• Medication tapering did not trigger disease flares.
• Those who reduced medications still achieved remission or meaningful clinical improvement.

While this was not a medication-withdrawal study, these findings raise the possibility that AIP may enhance the effectiveness of existing therapies or reduce inflammatory load sufficiently to support cautious step-down approaches in some patients.

Symptom improvements

Beyond remission scores, participants reported broad improvements in both digestive and systemic symptoms, including:

• Stool frequency and consistency
• Abdominal pain
• Bloating
• Fatigue
• Sleep quality
• Overall wellbeing

Notably, these subjective improvements closely aligned with objective measures of disease activity. This strengthens confidence in the reliability of patient-reported outcomes and suggests that participants were experiencing genuine physiological changes—not just perceived improvement.

Potential mechanisms behind symptom relief

Although the study did not directly measure mechanistic pathways, several plausible contributors may explain the observed improvements:

• Reduced exposure to common dietary irritants
• Increased intake of healing nutrients such as collagen, omega-3 fats, polyphenols, and essential minerals
• Improved gut barrier integrity
• Downregulation of inflammatory cytokines through dietary and lifestyle changes

This multifaceted effect is central to AIP’s design. Rather than targeting a single pathway, the protocol simultaneously addresses gut health, immune regulation, nutrient repletion, and systemic inflammation. That layered approach may help explain why improvements appeared both broad and rapid.

Interpretation: Why These Results Are Important

This study provided some of the earliest clinical evidence that AIP may help induce remission in individuals who have not fully responded to medication alone.

The rapid timeline of improvement raises several important hypotheses:

• Dietary change may influence gut inflammation more quickly than previously believed.
• Symptom relief may begin during early reductions in inflammatory foods, even before full elimination is implemented.
• Nutrient density may play a central mechanistic role, potentially influencing mucosal healing, microbial balance, and immune regulation.

Importantly, these findings did not stand in isolation. Subsequent mechanistic analyses and follow-up studies have supported similar patterns of improvement, strengthening the case that the results were not random or purely placebo-driven.

While larger randomized trials are still needed, this pilot study marked a pivotal moment in AIP research—demonstrating that structured dietary intervention could produce measurable, clinically meaningful changes in inflammatory bowel disease.

Study 2: Quality-of-Life Outcomes (Chandrasekaran et al., 2019)

While clinical remission is critical, chronic illness is also measured by how people feel and function. This follow-up publication from the same research team focused on patient-reported quality of life.

Study Design

In this follow-up analysis, researchers focused specifically on quality of life using the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), a validated tool commonly used in IBD research.

The SIBDQ measures multiple dimensions of daily life affected by inflammatory bowel disease, including:

• Daily functioning
• Emotional wellbeing
• Social functioning
• Systemic symptoms

Assessments were collected at baseline and again at weeks 3, 6, 9, and 11 throughout the intervention period, allowing researchers to track both early and sustained changes over time.

A total score above 50 is considered reflective of good quality of life.

Tracking these scores over time allowed researchers to evaluate both the speed and durability of improvement as participants progressed through the transition and elimination phases of AIP.

Study 2 Results

This follow-up study examined patient-reported quality of life, offering insight into how AIP affects daily functioning—not just clinical disease activity scores.

SIBDQ Outcomes

At baseline, the average SIBDQ score was 46.5, reflecting poor quality of life. By week 11, the average score had increased to 61.5—well into the range considered good quality of life.

This represents a clinically meaningful improvement. Participants were not only experiencing measurable changes in inflammation, but tangible improvements in how they felt and functioned in everyday life.

Improvements Across Symptom Domains

Participants reported gains across all four SIBDQ domains.

• In the area of bowel symptoms, many described fewer urgent bowel movements, less abdominal discomfort, and more predictable digestion.
• Systemic symptoms also improved, with participants noting reduced fatigue, better sleep, and fewer headaches or generalized body aches.
• Emotional wellbeing showed measurable gains, including improved mood, less stress reactivity, and greater confidence in managing symptoms.
• Social functioning improved as well. Participants reported increased participation in social activities and reduced anxiety surrounding food choices or potential flares.

Importantly, these quality-of-life improvements closely paralleled the remission findings from the initial study, reinforcing that symptom relief was both measurable and meaningful.

Interpretation: Why Quality of Life Matters in IBD

Quality of life often declines early in the course of IBD—sometimes even before formal diagnosis—and it does not always fully recover with medication alone. Many patients report that fatigue, unpredictability, and anxiety about symptoms are more disruptive than bowel symptoms themselves.

The finding that AIP improved quality of life as much as, and in some cases more than, objective disease markers suggests a broader therapeutic effect. Improvements may reflect combined changes in inflammatory burden, nutrient status, gut–brain axis regulation, stress resilience, and foundational lifestyle patterns.

Similar quality-of-life improvements have been observed in AIP studies on Hashimoto’s thyroiditis and rheumatoid arthritis, further supporting the idea that AIP’s influence extends beyond a single organ system and may help regulate immune and inflammatory processes more broadly.

Study 3: RNA Expression Analysis (Chandrasekaran et al., 2019)

This mechanistic study examined whether AIP changes immune function at the tissue level—a key question for understanding how and why the protocol works.

Study Design

In this companion mechanistic study, researchers analyzed colon biopsy samples from four participants with ulcerative colitis who completed the AIP intervention.

Biopsies were collected before and after the dietary program. Using RNA sequencing technology, investigators evaluated changes in gene expression within the intestinal tissue itself. This approach allowed them to examine how AIP may influence inflammatory signaling directly at the site of disease.

Specifically, they assessed gene expression patterns associated with:

• Inflammation
• Tissue injury and repair
• Immune system regulation
• Mucosal healing pathways

By analyzing molecular changes in the gut lining, this study moved beyond symptom reporting and clinical scores to explore potential biological mechanisms underlying the improvements observed in remission and quality of life outcomes.

Study 3 Results

This mechanistic study evaluated whether AIP produces measurable changes at the gene expression level within inflamed intestinal tissue.

Researchers compared colon biopsy samples collected before and after the AIP intervention in four participants with ulcerative colitis.

Differential Gene Expression

A total of 324 genes were significantly altered following the intervention.

167 genes were downregulated, many of which were involved in pro-inflammatory pathways—particularly those related to T-cell activation. This pattern suggests a reduction in immune overactivation and aligns closely with the clinical remission patterns observed in the primary study.

157 genes were upregulated, with many associated with immune regulation, epithelial repair, and DNA maintenance. These changes suggest enhanced mucosal healing and activation of protective, restorative processes within the intestinal lining.

Together, these findings provide biological context for the symptomatic and clinical improvements reported in the earlier studies. Rather than reflecting only subjective improvement, the results indicate measurable shifts in inflammatory and repair pathways at the tissue level.

Interpretation: What Gene Expression Changes Suggest

Gene expression analysis offers a direct window into the cellular impact of AIP. Rather than measuring symptoms alone, this data helps us understand what may be happening inside the intestinal tissue itself.

Several key themes emerged from the findings:

• AIP may reduce inflammatory signaling at the tissue level.
  This aligns with the improved symptoms and remission rates observed in the clinical study.
• Mucosal healing pathways may activate early.
  Mucosal healing is one of the strongest predictors of long-term remission in IBD, making this shift particularly meaningful.
• Dietary patterns can influence immune gene expression within weeks.
  This challenges the long-held assumption that dietary interventions require extended timeframes to impact cellular behavior.
• Upregulation of regulatory pathways may help shift the immune system from reactive to restorative modes.
  Rather than simply suppressing inflammation, these changes suggest enhanced immune balance and repair.

Importantly, these mechanisms mirror findings from AIP research in Hashimoto’s thyroiditis, where participants demonstrated reductions in inflammatory markers such as hs-CRP alongside improved symptom burden. Together, this suggests that AIP may exert broader immune-regulating effects across autoimmune conditions—not just within the gut.

Study 4: Long-Term Outcomes and Food Reintroductions (Lee et al., 2019)

This follow-up study examined how AIP performed after the structured clinical trial ended. Researchers evaluated whether remission was maintained over time and how participants navigated food reintroductions in a real-world setting.

By focusing on durability and sustainability, this study helped determine whether AIP functions as a practical long-term framework—not just a short-term intervention.

Study Design

In this observational follow-up study, researchers surveyed 78 individuals with Crohn’s disease or ulcerative colitis who had implemented AIP independently, without formal coaching or structured trial oversight.

Participants completed questionnaires detailing their:

• Disease history
• Symptom progression over time
• Medication use
• Approach to AIP implementation
• Food reintroductions and reactions
• Factors influencing long-term sustainability

By examining self-directed use of AIP, this study aimed to better understand how the protocol performs outside of a controlled research environment and how individuals adapt it in real-world settings.

Study 4 Results

This study captured real-world outcomes from 78 individuals with Crohn’s disease or ulcerative colitis who implemented AIP independently, outside of a structured clinical program.

Clinical Outcomes

Seventy-three percent of participants reported achieving remission, and 32% were able to discontinue steroid use. These findings closely mirror the results seen in the original clinical study, suggesting that AIP’s benefits may extend beyond supervised research settings and into self-directed use.

Food Reintroductions and Long-Term Flexibility

One of the most important aspects of this study was its evaluation of the reintroduction phase. Most participants began reintroducing foods sometime between five weeks and one year after starting AIP. Over time, many were able to successfully reintroduce a variety of foods, identify their personal trigger foods, and maintain greater dietary flexibility.

These findings support the central goal of AIP: not long-term restriction, but personalization. The data suggest that most individuals were able to expand their diets meaningfully while maintaining symptom control.

Commonly Reported Trigger Foods

Participants identified several foods as most likely to trigger symptom recurrence:

• Gluten (58%)
• Processed foods (52%)
• Nightshades (46%)
• Dairy (42%)
• Non-gluten grains (29%)

These patterns align with both clinical experience and broader research examining dietary contributors to inflammation in autoimmune disease.

Interpretation: Why Real-World Data is Important

This study adds an essential dimension to the research on AIP. While clinical trials demonstrate that the protocol is feasible and can produce meaningful short-term results, real-world data helps answer a different question: Is it sustainable?

The findings suggest that AIP can be adapted to diverse lifestyles and implemented without formal supervision. Participants reported maintaining symptom improvements over time, navigating reintroductions successfully, and integrating the framework into their social, cultural, and personal food preferences.

Rather than remaining rigid or restrictive, long-term use appeared to become increasingly personalized and flexible. This pattern aligns with broader AIP research, which consistently shows that the protocol functions best as a structured learning process—one that ultimately leads to an individualized, sustainable approach to nutrition.